Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Dr Reddys Laboratories ADR repsg 1 Ord Shs RDY

Healthcare
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The... see more

Recent & Breaking News (NYSE:RDY)

Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F

Business Wire June 4, 2019

Dr. Reddy's Laboratories Announces the Re-Launch of Zenatane® (Isotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg in the U.S. Market

Business Wire June 3, 2019

Dr. Reddy's Q4 & FY19 Financial Results

Business Wire May 17, 2019

Dr. Reddy's Laboratories announces the launch of Daptomycin for Injection, 500mg/vial single-dose vial in the U.S. Market

Business Wire May 15, 2019

Dr. Reddy's Laboratories Announces the Launch of Testosterone Gel, 1.62% (20.25 mg/1.25 g Pump Actuation) in the U.S. Market

Business Wire May 6, 2019

URGENT: Monteverde & Associates PC Invites Dr. Reddy's Laboratories Ltd. Shareholders or Former Shareholders To Contact the Firm Immediately

PR Newswire May 1, 2019

Dr. Reddy's to Release Q4 and Full Year FY 19 Results on May 17, 2019

Business Wire April 17, 2019

Dr. Reddy's Laboratories Announces Acquisition of ANDA Portfolio

Business Wire April 13, 2019

The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

Benzinga.com  April 3, 2019

Promius Pharma, LLC. (a Wholly Owned Subsidiary of Dr. Reddy’s Laboratories Ltd.) Announces the Sale and Assignment of the US Rights for Its Marketed Dermatology Brands to Encore Dermatology

Business Wire April 2, 2019

Dr. Reddy's Laboratories launches Tadalafil Tablets USP in the U.S. Market

Business Wire March 27, 2019

Dr. Reddy's Laboratories Announces the Re-Launch of Its Buprenorphine and Naloxone Sublingual Film after Favorable Ruling in Patent Litigation

Business Wire February 20, 2019

Dr. Reddy's Laboratories launches Tadalafil Tablets USP in the U.S. Market

Business Wire February 12, 2019

Dr. Reddy's Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling

Business Wire February 4, 2019

Dr. Reddy's Announces the Appointment of Marc Kikuchi to Lead Its Generics Business in North America

Business Wire February 1, 2019

Dr. Reddy’s Q3 FY19 Financial Results

Business Wire February 1, 2019

Dr. Reddy's Laboratories and Its U.S. Subsidiary, Promius Pharma, Announce FDA Approval for TOSYMRA™ (Sumatriptan Nasal Spray) 10 mg, in the U.S. Market

Business Wire January 27, 2019

Dr. Reddy's Laboratories Announces the Launch of Propofol Injectable Emulsion, USP in the U.S. Market

Business Wire January 24, 2019

Dr. Reddy's to Release Q3 FY19 Results on February 1, 2019

Business Wire January 11, 2019

Dr. Reddy's Laboratories Limited to Present at the 37th Annual J.P. Morgan Healthcare Conference

Business Wire January 7, 2019